Are you still here? That is fantastic! That must mean you made a conscious, all-in decision to start a dry eye practice, as discussed in part 1, and you have adjusted your existing protocols to include a directed evaluation of the anterior segment looking for clues to the presence and type of dry eye using our traditional exam techniques, as discussed in part 2. You have started to use the information you have gathered to treat patients who suffer from dry eye symptoms using a combination of artificial tears, mechanical therapy and prescription medications. Guess what? Your patients have noticed, and they feel better.I promised you that treating dry eye would make you cool, like our up-and-coming thought leaders Elizabeth Yeu, MD, and Christopher Starr, MD, but you probably were still a bit skeptical, weren’t you? Right up until you walked by the Abbott Medical Optics booth at the American Academy of Ophthalmology meeting and noticed that the longest line was not for the sweets or the sweet lasers, but to sign up for Blink samples. Admit it, that is kind of cool. Now it is time to take the next step like Liz and Chris and become an advanced dry eye practice.
Finding the Optimal Treatment Plan for Exudative AMD
This review examines dosing strategies to optimize treatment outcomes of anti-VEGF therapies. Which regimen is most effective? International Ophthalmology Clinics
VIDEO: Argus II implantations yield positive results
FLORENCE, Italy — At the FLOREtina meeting, Fernando Arevalo, MD, reports on his experience with the implantation of the Argus II retinal prosthesis (Second Sight) in seven patients.
Myopia-related differences in eye structure may help in developing ‘customized’ intraocular lenses
The presence of myopia, or nearsightedness, significantly affects the muscles used in focusing the lens of the eye-a finding with important implications for the development of “accommodating”…
Valeant forms interim office as CEO goes on medical leave of absence
Valeant Pharmaceutical International announced in a press release that J. Michael Pearson, its chairman and CEO, is on medical leave of absence. An Office of the Chief Executive Officer has been created by Valeant’s board of directors and will include Robert Chai-Onn, executive vice president and general counsel, Ari Kellen, MBBCh, MBA, executive vice president and company chairman, and Robert Rosiello, executive vice president and chief financial officer, who will serve in an interim capacity, according to the release.
VIDEO: New technology changes patient care in ophthalmology
MIAMI — At the CEDARS/ASPENS meeting, William B. Trattler, MD, talks about the LipiView (TearScience) and how the technology has changed the way physicians care for patients.